169 related articles for article (PubMed ID: 36731023)
21. Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment.
Leon-Castillo A; Horeweg N; Peters EEM; Rutten T; Ter Haar N; Smit VTHBM; Kroon CD; Boennelycke M; Hogdall E; Hogdall C; Nout RRA; Creutzberg CL; Ortoft G; Bosse T
Gynecol Oncol; 2022 Mar; 164(3):577-586. PubMed ID: 35078648
[TBL] [Abstract][Full Text] [Related]
22. Harmonized molecular classification; assessment of a single-test ProMisE NGS tool.
Jamieson A; McConechy MK; Lum A; Leung S; Thompson EF; Senz J; Talhouk A; Huntsman DG; Bashashati A; Gilks CB; McAlpine JN
Gynecol Oncol; 2023 Aug; 175():45-52. PubMed ID: 37321155
[TBL] [Abstract][Full Text] [Related]
23. The clinicopathological characteristics of POLE-mutated/ultramutated endometrial carcinoma and prognostic value of POLE status: a meta-analysis based on 49 articles incorporating 12,120 patients.
Wu Q; Zhang N; Xie X
BMC Cancer; 2022 Nov; 22(1):1157. PubMed ID: 36357827
[TBL] [Abstract][Full Text] [Related]
24. Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer.
Proctor L; Pradhan M; Leung S; Cheng A; Lee CH; Soslow RA; Gilks CB; Talhouk A; McAlpine JM; Danielsen HE; Hoang LN
Gynecol Oncol; 2017 Sep; 146(3):596-602. PubMed ID: 28647100
[TBL] [Abstract][Full Text] [Related]
25. POLE, MMR, and MSI Testing in Endometrial Cancer: Proceedings of the ISGyP Companion Society Session at the USCAP 2020 Annual Meeting.
Casey L; Singh N
Int J Gynecol Pathol; 2021 Jan; 40(1):5-16. PubMed ID: 33290350
[TBL] [Abstract][Full Text] [Related]
26. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma.
Britton H; Huang L; Lum A; Leung S; Shum K; Kale M; Burleigh A; Senz J; Yang W; McConechy M; Kommoss S; Brucker S; Talhouk A; Gilks CB; McAlpine JN
Gynecol Oncol; 2019 Jun; 153(3):487-495. PubMed ID: 30922603
[TBL] [Abstract][Full Text] [Related]
27. Molecular characterization in the prediction of disease extent in endometrial carcinoma.
Kolehmainen AM; Pasanen AM; Koivisto-Korander RL; Bützow RC; Loukovaara MJ
Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():478-483. PubMed ID: 33189427
[TBL] [Abstract][Full Text] [Related]
28. Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification.
Kim SR; Cloutier BT; Leung S; Cochrane D; Britton H; Pina A; Storness-Bliss C; Farnell D; Huang L; Shum K; Lum A; Senz J; Lee CH; Gilks CB; Hoang L; McAlpine JN
Gynecol Oncol; 2020 Jul; 158(1):3-11. PubMed ID: 32331700
[TBL] [Abstract][Full Text] [Related]
29. Validation of a one-step genomics-based molecular classifier for endometrial carcinoma in a large Chinese population.
Kang N; Zhang X; Wang Z; Dai Y; Lu S; Su W; Gai F; Zhu C; Shen D; Wang J
Pathol Res Pract; 2024 Feb; 254():155152. PubMed ID: 38277742
[TBL] [Abstract][Full Text] [Related]
30. [Clinical application of TCGA molecular classification in endometrial endometrioid carcinoma].
Du NN; Liu Y; Ren CX; Wang YX; Du J; Yang J; Liu CR
Zhonghua Bing Li Xue Za Zhi; 2019 Aug; 48(8):596-603. PubMed ID: 31422589
[No Abstract] [Full Text] [Related]
31. Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer.
Raffone A; Travaglino A; Gabrielli O; Micheli M; Zuccalà V; Bitonti G; Camastra C; Gargiulo V; Insabato L; Zullo F
Arch Gynecol Obstet; 2021 Jun; 303(6):1393-1400. PubMed ID: 33754186
[TBL] [Abstract][Full Text] [Related]
32. p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial.
Vermij L; Léon-Castillo A; Singh N; Powell ME; Edmondson RJ; Genestie C; Khaw P; Pyman J; McLachlin CM; Ghatage P; de Boer SM; Nijman HW; Smit VTHBM; Crosbie EJ; Leary A; Creutzberg CL; Horeweg N; Bosse T;
Mod Pathol; 2022 Oct; 35(10):1475-1483. PubMed ID: 35752743
[TBL] [Abstract][Full Text] [Related]
33. Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma.
Rios-Doria E; Momeni-Boroujeni A; Friedman CF; Selenica P; Zhou Q; Wu M; Marra A; Leitao MM; Iasonos A; Alektiar KM; Sonoda Y; Makker V; Jewell E; Liu Y; Chi D; Zamarin D; Abu-Rustum NR; Aghajanian C; Mueller JJ; Ellenson LH; Weigelt B
Gynecol Oncol; 2023 Jul; 174():262-272. PubMed ID: 37245486
[TBL] [Abstract][Full Text] [Related]
34. Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup.
Hoang LN; Kinloch MA; Leo JM; Grondin K; Lee CH; Ewanowich C; Köbel M; Cheng A; Talhouk A; McConechy M; Huntsman DG; McAlpine JN; Soslow RA; Gilks CB
Am J Surg Pathol; 2017 Feb; 41(2):245-252. PubMed ID: 28079598
[TBL] [Abstract][Full Text] [Related]
35. Analysis of patients with endometrial carcinoma using the ProMise classifier: a pilot study from India.
Dahiya A; Rajadurai A; Daniel S; Sebastian A; Thomas DS; Thomas V; George R; Ram TS; Sathyamurthy A; Rebekah G; Peedicayil A; Pai R; Thomas A
Arch Gynecol Obstet; 2024 Apr; 309(4):1499-1508. PubMed ID: 37707553
[TBL] [Abstract][Full Text] [Related]
36. Combination of Proactive Molecular Risk Classifier for Endometrial cancer (ProMisE) with sonographic and demographic characteristics in preoperative prediction of recurrence or progression of endometrial cancer.
Eriksson LSE; Nastic D; Lindqvist PG; Imboden S; Järnbert-Pettersson H; Carlson JW; Epstein E
Ultrasound Obstet Gynecol; 2021 Sep; 58(3):457-468. PubMed ID: 33314410
[TBL] [Abstract][Full Text] [Related]
37. Corded and Hyalinized and Spindled Endometrioid Endometrial Carcinoma: A Clinicopathologic and Molecular Analysis of 9 Tumors Based on the TCGA Classifier.
Safdar NS; Thompson EF; Gilks CB; Isacson C; Bennett JA; Clarke B; Young RH; Oliva E
Am J Surg Pathol; 2021 Aug; 45(8):1038-1046. PubMed ID: 34115671
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma.
Pasanen A; Loukovaara M; Bützow R
Mod Pathol; 2020 Jul; 33(7):1443-1452. PubMed ID: 32060377
[TBL] [Abstract][Full Text] [Related]
39. Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma.
Brett MA; Atenafu EG; Singh N; Ghatage P; Clarke BA; Nelson GS; Bernardini MQ; Köbel M
Int J Gynecol Pathol; 2021 Mar; 40(2):116-123. PubMed ID: 32265358
[TBL] [Abstract][Full Text] [Related]
40. "Surface epithelial slackening" pattern in endometrioid carcinoma: A morphological feature for differentiating the POLE mutation-subtype from the no specific molecular profile subtype.
Kitazono I; Akahane T; Yokoyama S; Kobayashi Y; Togami S; Yanazume S; Tasaki T; Noguchi H; Tabata K; Kobayashi H; Tanimoto A
Pathol Res Pract; 2023 Jul; 247():154563. PubMed ID: 37229919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]